{"slideshow_credits": null, "snippet": "Venture philanthropy risks benefiting companies, not patients.", "abstract": "Op-Ed article by journalist Llewellyn Hinkes-Jones opposes the rise of so-called 'venture philanthropy' in the pharmaceutical industry; calls it yet another term for privatizing scientific research; holds trend introduces tax-exempt loophole, allowing organizations to develop drugs on publicly funded research and then sell results to private industry; calls for increased funding to the National Institutes of Health, and for rule that would prevent venture philanthropists from obtaining exclusive patent rights.", "section_name": "Opinion", "print_page": "23", "document_type": "article", "byline": {"person": [{"firstname": "Llewellyn", "role": "reported", "lastname": "HINKES-JONES", "rank": 1, "organization": ""}], "original": "By LLEWELLYN HINKES-JONES", "contributor": ""}, "web_url": "http://www.nytimes.com/2015/01/06/opinion/stop-subsidizing-big-pharma.html", "lead_paragraph": "Venture philanthropy risks benefiting companies, not patients.", "headline": {"print_headline": "Stop Subsidizing Big Pharma", "main": "Stop Subsidizing Big Pharma", "content_kicker": "Op-Ed Contributor", "kicker": "Op-Ed Contributor"}, "_id": "54ab34ab38f0d83eda14cc57", "word_count": "748", "multimedia": [{"height": 126, "url": "images/2015/01/06/opinion/06HinkesJones/06HinkesJones-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/01/06/opinion/06HinkesJones/06HinkesJones-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 438, "url": "images/2015/01/06/opinion/06HinkesJones/06HinkesJones-articleLarge.jpg", "legacy": {"xlarge": "images/2015/01/06/opinion/06HinkesJones/06HinkesJones-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "438"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/01/06/opinion/06HinkesJones/06HinkesJones-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/01/06/opinion/06HinkesJones/06HinkesJones-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-01-06T00:00:00Z", "source": "The New York Times", "news_desk": "OpEd", "keywords": [{"name": "subject", "value": "Philanthropy", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "National Institutes of Health", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Tax Credits, Deductions and Exemptions", "is_major": "Y", "rank": "4"}, {"name": "subject", "value": "Research", "is_major": "Y", "rank": "5"}, {"name": "subject", "value": "Corporate Taxes", "is_major": "N", "rank": "6"}, {"name": "subject", "value": "Biotechnology and Bioengineering", "is_major": "N", "rank": "7"}, {"name": "organizations", "value": "Cystic Fibrosis Foundation", "is_major": "N", "rank": "8"}, {"name": "organizations", "value": "Vertex Pharmaceuticals Inc", "is_major": "N", "rank": "9"}, {"name": "subject", "value": "Royalties", "is_major": "N", "rank": "10"}], "blog": [], "subsection_name": null, "type_of_material": "Op-Ed"}